Kodiak Q3 net loss $67.5M ($1.30/shr); cash $799M; pipeline on track for 2022 readouts

Kodiak Sciences Inc.

2022-Q3 EPS reported -$3.36

Net loss widened to $67.5M ($1.30/shr) from $36.1M ($0.80/shr) in Q3 2020.
R&D expenses rose to $56.0M (vs $29.3M) on KSI-301 trial and manufacturing costs.
Cash and equivalents $799.2M; no revenue reported.
DAZZLE (wet AMD) topline data expected Q1 2022; BEACON (RVO) mid-2022.
GLEAM/GLIMMER (DME) enrollment target Q1 2022; DAYLIGHT (wet AMD) enrollment 1H 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.